WO2000015207B1 - Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) - Google Patents

Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)

Info

Publication number
WO2000015207B1
WO2000015207B1 PCT/IB1999/001547 IB9901547W WO0015207B1 WO 2000015207 B1 WO2000015207 B1 WO 2000015207B1 IB 9901547 W IB9901547 W IB 9901547W WO 0015207 B1 WO0015207 B1 WO 0015207B1
Authority
WO
WIPO (PCT)
Prior art keywords
syn
combination
group
antibacterial agent
piperaciilin
Prior art date
Application number
PCT/IB1999/001547
Other languages
French (fr)
Other versions
WO2000015207A2 (en
WO2000015207A3 (en
Inventor
Samarendra N Maiti
O A Phillips
Sameeh Salama
Ronald G Micetich
Original Assignee
Naeja Pharmaceutical Inc
Samarendra N Maiti
O A Phillips
Sameeh Salama
Ronald G Micetich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naeja Pharmaceutical Inc, Samarendra N Maiti, O A Phillips, Sameeh Salama, Ronald G Micetich filed Critical Naeja Pharmaceutical Inc
Priority to AU55282/99A priority Critical patent/AU5528299A/en
Publication of WO2000015207A2 publication Critical patent/WO2000015207A2/en
Publication of WO2000015207A3 publication Critical patent/WO2000015207A3/en
Publication of WO2000015207B1 publication Critical patent/WO2000015207B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method of treatment is provided to treat inflammation associated with human neutrophil elastase mediated disorders, particularly diseases of respiratory system or oral cavity. The method comprises a combined therapy of administering an elastase inhibitor(s) with an antibacterial agent(s), directed against pathogenic bacteria associated with disease of the respiratory system and oral cavity. A pharmaceutical composition comprising at least one antibacterial agent, and at least one elastase inhibitor is provided, preferably in aerosolized form, as well as a kit containing the respective components in separate packages.

Claims

AMENDED CLAIMS
[received by the International Bureau on 12 May 2000 (12.05.00); new claims 23-25 added; remaining claims unchanged (3 pages)] piperaciilin and tazobactam, the combination of ticarcillin and clavulanic acid, BMS-180680, norfloxacin, ciprofloxacin, ofloxacin, lomefloxacin, pefloxacin, rufloxacin, sparfloxacin, tobramycin, amikacin, gentamicin, netlimicin, erythromycin, clarithromycin, azithromycin, tetracycline, oxytetracycline, doxycycline, minocycline, IB-367, daptomycin, triclosan; and pharmaceutically acceptable salts of any of said antibacterial agents.
18. A kit according to claim 15, wherein said antibacterial agent is daptomycin.
19. A kit according to claim 15, wherein said antibacterial agent is IB-367.
20. A kit according to claim 15, wherein said antibacterial agent is tobramycin, and wherein said elastase inhibitor is SYN 1390 or SYN 1396.
21. A kit according to claim 15, wherein said elastase mediated disorder is a pulmonary disease selected from the group consisting of cystic fibrosis (CF), chronic bronchitis, and bronchiectasis.
22. A kit according to claim 15, wherein said elastase mediated disorder is a dental disease selected from the group consisting of periodontitis or gingivitis.
23. A method according to claim 1 , wherein said antibacterial agent is selected from the group consisting of ceftazidime, cefpirome, cefepime, cefoperazone, imipenem, meropenem, piperaciilin, mezlocillin, ticarcillin, the combination of piperaciilin and tazobactam, the combination of ticarcillin and clavulanic acid, BMS-180680, norfloxacin, ciprofloxacin, ofloxacin, lomefloxacin, pefloxacin, rufloxacin, sparfloxacin, tobramycin, amikacin, gentamicin, netlimicin, erythromycin, clarithromycin, azithromycin, tetracycline, oxytetracycline, doxycycline, minocycline, IB-367, daptomycin, triclosan; and pharmaceutically acceptable salts of any of said antibacterial agents; and said elastase
14 inhibitor is selected from the group consisting of DMP 777; ONO 5046; ICI 200,800; ICI
200,355; L-658, 758; L-659, 286; CE-1037; SYN 1390; SYN 1396; SLPI; and αrAT.
24. A pharmaceutical composition according to claim 10, wherein said antibacterial agent is selected from the group of antibacterial agents consisting of ceftazidime, cefpirome, cefepime, cefoperazone, imipenem, meropenem, piperaciilin, mezlocillin, ticarcillin, the combination of piperaciilin and tazobactam, the combination of ticarcillin and clavulanic acid, BMS-180680, norfloxacin, ciprofloxacin, ofloxacin, lomefloxacin, pefloxacin, rufloxacin, sparfloxacin, tobramycin, amikacin, gentamicin, netlimicin, erythromycin, clarithromycin, azithromycin, tetracycline, oxytetracycline, doxycycline, minocycline, IB-367, daptomycin, triclosan; and pharmaceutically acceptable salts of any of said antibacterial agents and said elastase inhibitor is selected from the group consisting of DMP 777; ONO
5046; ICI 200,800; ICI 200,355; L-658, 758; L-659, 286; CE-1037; SYN 1390; SYN 1396; SLPI; and αrAT.
25. A kit according to claim 15, wherein said antibacterial agent is an agent selected from the group consisting of ceftazidime, cefpirome, cefepime, cefoperazone, imipenem, meropenem, piperaciilin, mezlocillin, ticarcillin, the combination of piperaciilin and tazobactam, the combination of ticarcillin and clavulanic acid, BMS-180680, norfloxacin, ciprofloxacin, ofloxacin, lomefloxacin, pefloxacin, rufloxacin, sparfloxacin, tobramycin, amikacin, gentamicin, netlimicin, erythromycin, clarithromycin, azithromycin, tetracycline, oxytetracycline, doxycycline, minocycline, IB-367, daptomycin, triclosan; and pharmaceutically acceptable salts of any of said antibacterial agents and said elastase inhibitor is selected from the group consisting of DMP 777; ONO 5046; ICI 200,800; ICI
15
AMENDED SHEET (ARTICLE 10f 200,355; L-658, 758; L-659, 286; CE-1037; SYN 1390; SYN 1396; SLPI; and αrAT.
16
PCT/IB1999/001547 1998-09-15 1999-09-15 Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s) WO2000015207A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU55282/99A AU5528299A (en) 1998-09-15 1999-09-15 Combined therapy for treatment of inflammation using elastase inhibitor(s) and antibacterial agent(s)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10038698P 1998-09-15 1998-09-15
US60/100,386 1998-09-15

Publications (3)

Publication Number Publication Date
WO2000015207A2 WO2000015207A2 (en) 2000-03-23
WO2000015207A3 WO2000015207A3 (en) 2000-05-25
WO2000015207B1 true WO2000015207B1 (en) 2000-07-13

Family

ID=22279479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1999/001547 WO2000015207A2 (en) 1998-09-15 1999-09-15 Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)

Country Status (2)

Country Link
AU (1) AU5528299A (en)
WO (1) WO2000015207A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2728301A (en) * 2000-01-06 2001-07-16 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
US6552082B2 (en) 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
EP1367980A2 (en) * 2001-02-13 2003-12-10 Intrabiotics Pharmaceuticals, Incorporated Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial ib-367 peptides
AU2004210399B2 (en) * 2003-02-10 2010-02-18 Bayer Intellectual Property Gmbh Treatment of bacterial diseases of the respiratory organs by locally applying fluoroquinolones
DE10350409A1 (en) * 2003-10-28 2005-05-25 Bayer Healthcare Ag Method employing quinolones and related substances for treatment and prophylaxis of genetic diseases causing local mutations and comparable defects in higher organisms, including human beings
CN108570418A (en) * 2018-04-08 2018-09-25 山东农业大学 A kind of aspergillus fumigatus agar beads and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1564317A (en) * 1976-06-25 1980-04-10 Roche Products Ltd Dipeptide derivatives
IL69795A (en) * 1983-09-23 1987-01-30 Univ Ramot Ophthalmic preparations containing as active ingredient 2-mercaptoalkanoyl peptides
US5439904A (en) * 1993-12-07 1995-08-08 Synphar Laboratories, Inc. 2-spiro(2'-spirocycloalkyl)cyclopropyl cephalosporin sulfones as antiinflammatory and antigenerative agents

Also Published As

Publication number Publication date
WO2000015207A2 (en) 2000-03-23
WO2000015207A3 (en) 2000-05-25
AU5528299A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
US5770588A (en) Non-antibacterial tetracycline compositions of the prevention and treatment of root caries
EP2135615B1 (en) Compositions comprising extracts from sanguinaria or macleaya
BR0109875A (en) Treatment of respiratory diseases
Greenstein Povidone‐iodine's effects and role in the management of periodontal diseases: a review
ES2136883T3 (en) NEW IMPROVED FORMULATION OF AMINOGLUCOSIDE FOR ADMINISTRATION IN THE FORM OF AEROSOL.
CA2316919A1 (en) Novel macrolides
NZ510690A (en) Methods for administration of antibiotics
CA2289717A1 (en) Novel therapy for constipation
CA2351429A1 (en) 13-membered azalides and their use as antibiotic agents
CA2414576A1 (en) Promoting whole body health
CA2293823A1 (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
CA2293397A1 (en) C-4''-substituted macrolide derivatives
CA2982943C (en) Compositions and methods for treating bacterial infection
AU685075B2 (en) Pharmaceutical composition for treating nicotine dependence
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
WO2000015207B1 (en) Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
RU94008616A (en) 2-THIOSUBLISHED CARBAPENES, INTERMEDIATE CONNECTIONS FOR OBTAINING, METHODS OF OBTAINING, PHARMACEUTICAL COMPOSITION, METHOD OF TREATING BACTERIAL INFECTIONS
BR9812577A (en) Compound, process for preparing the same, pharmaceutical composition, and process for treating bacterial infections
ES2133722T3 (en) USE OF SIMPLE OR CONJUGATED DEXTRANS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO PREVENT OR REDUCE THE RISK OF INFECTION OF BACTERIAL PATHOGENIC GERMS.
WO2003059246A3 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
WO1998052576A1 (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
EP2138175A3 (en) Formulations comprising valsartan for treating diabetes or microalbuminuria
WO2001082945B1 (en) The use of bacterial phage associated lysing enzymes for treating various illnesses
WO2002069887A3 (en) Virucidal compositions
BR0006301A (en) Antibacterial and prokinetic macrolides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 09786372

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase